» Articles » PMID: 22503506

Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Non-small-cell Lung Cancers

Abstract

Background: Epidermal growth factor receptor (EGFR) is often overexpressed in non-small-cell lung cancer (NSCLC). Anti-EGFR agents, including EGFR-tyrosine kinase inhibitors are considered to be effective when a drug-sensitive EGFR mutation is present. However, inherent and acquired resistances are major problems of EGFR-targeting therapies. In this study, we performed EGFR knockdown by using small interfering RNAs in NSCLC cell lines to examine the significance of targeting EGFR for NSCLC therapy.

Methods: We treated 13 NSCLC cell lines, including 8 EGFR mutant and 5 EGFR wild type by using gefitinib or small interfering RNAs against EGFR (siEGFR). Three cell lines (PC-9-GR1, RPC-9, and HCC827-ER) were experimentally established with acquired resistance to EGFR-tyrosine kinase inhibitors. The antitumor effect was determined by using an 3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt (MTS) or colony formation assay. The protein expression was evaluated by using Western blotting.

Results: All 13 cell lines expressed EGFR protein, and siEGFR downregulated EGFR protein expression in all. The cell viability was suppressed by siEGFR in 6 of 8 EGFR-mutant cell lines (suppressed 57%-92% of control cells), including PC-9-GR1 and RPC-9. The NCI-H1650 and HCC827-ER harbored EGFR mutations but were not suppressed. Of note, PTEN (phosphatase and tensin homolog) was deleted in NCI-H1650, and c-MET was amplified in HCC827-ER. It was not suppressed in any of the EGFR wild-type cells except in the NCI-H411, in which EGFR is phosphorylated, which indicates its activation.

Conclusions: Analysis of the results indicated that EGFR can be a therapeutic target in NSCLCs with EGFR activation. In contrast, targeting EGFR is not appropriate for tumors in which EGFR is not activated, even if EGFR is expressed.

Citing Articles

EGFR is a potential dual molecular target for cancer and Alzheimer's disease.

Choi H, Jeong Y, Kim J, Hoe H Front Pharmacol. 2023; 14:1238639.

PMID: 37601068 PMC: 10433764. DOI: 10.3389/fphar.2023.1238639.


MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.

Li Q, Wang Y, He J J Clin Lab Anal. 2021; 35(7):e23853.

PMID: 34057242 PMC: 8274984. DOI: 10.1002/jcla.23853.


Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.

Yoshioka T, Shien K, Takeda T, Takahashi Y, Kurihara E, Ogoshi Y Cancer Sci. 2019; 110(8):2549-2557.

PMID: 31162771 PMC: 6676122. DOI: 10.1111/cas.14089.


Lentivirus-mediated silencing of HOTAIR lncRNA restores gefitinib sensitivity by activating Bax/Caspase-3 and suppressing TGF-α/EGFR signaling in lung adenocarcinoma.

Liu Y, Jiang H, Zhou H, Ying X, Wang Z, Yang Y Oncol Lett. 2018; 15(3):2829-2838.

PMID: 29467862 PMC: 5778865. DOI: 10.3892/ol.2017.7656.


Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

Yoshioka T, Shien K, Namba K, Torigoe H, Sato H, Tomida S Cancer Sci. 2018; 109(4):1166-1176.

PMID: 29465762 PMC: 5891184. DOI: 10.1111/cas.13546.